Login to Your Account



Clinic Roundup


Tuesday, December 14, 2010
Chimerix Inc., of Durham, N.C., said Phase I results demonstrated that CMX157 has a favorable safety, tolerability and drug distribution profile. In addition, results from preclinical studies showed that the drug exhibited potent in vivo activity against HIV, including HIV strains resistant to current therapies, and potent in vitro activity against xenotropic murine leukemia virus-related virus. Data were presented at the HIV DART 2010 meeting in Los Cabos, Mexico. CMX157 is a chemically modified version of tenofovir using the company's Phospholipid IntramembraneMicrofluidization Conjugate technology.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription